Phase I/II proof of concept trial of dCellVax in patients with metastatic breast cancer

Trial Profile

Phase I/II proof of concept trial of dCellVax in patients with metastatic breast cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs IDO-silenced dendritic cell vaccine Regen BioPharma (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Regen BioPharma
  • Most Recent Events

    • 14 Sep 2016 According to Regen BioPharma media release, the company has announced submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application.
    • 27 May 2015 According to a Regen BioPharma media release, the company is currently in the process of addressing FDA questions related to the submitted IND (IND #16200) before starting the clinical trial.
    • 09 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top